Table II.

AASLD and EASL recommendations regarding COVID-19 vaccination for patients with chronic liver disease and liver transplant recipients.

Type of vaccine	Vaccine	Administration	Booster dose	Population
mRNA-based	mRNA-1273 (Moderna)	Three doses	Bivalent ≥2 months after primary series	Age, ≥6 months (Pfizer-BioNTech bivalent booster recommended for ages 12-17 years; Moderna or Pfizer-BioNTech bivalent booster recommended for ages ≥18 years)
	BNT162b2 (BioNTech and Pfizer) vaccine	Three doses	Bivalent ≥2 months after primary series	Age, ≥6 months (Pfizer-BioNTech bivalent booster recommended for ages 12-17 years; Moderna or Pfizer-BioNTech bivalent booster recommended for ages ≥18 years)
Adenovirus vector-based	Ad26.COV2-S vaccine (Johnson & Johnson)	Single dose followed by mRNA vaccine	Bivalent ≥2 months after primary series	Age, ≥18 years (mRNA primary vaccine series preferred whenever possible)
Protein subunit vaccines	Novavax (NVX-CoV2373)	Two doses	Bivalent ≥2 months after primary series	Age, ≥12 years

AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study of the Liver; COVID-19, coronavirus disease 2019.